Dr. Donald Tomalia is a world-renowned leader in molecular research and the creator of dendrimers. He is Director of the National Dendrimer & Nanotechnology Center and Distinguished Professor/Research Scientist in the Department of Chemistry - Central Michigan University and external faculty at the University of Wisconsin (Madison)- School of Pharmacy.
Donald A. Tomalia is the CEO/Founder of NanoSynthons LLC and National Dendrimer & Nanotechnology Center; Adjunct Professor (Department of Chemistry) University of Pennsylvania, PA and Affiliate Professor (Department of Physics) Virginia Commonwealth University, VA.
Dr. Tomalia received his B.A. in Chemistry from the University of Michigan and Ph.D. in Physical-Organic Chemistry from Michigan State University while working at The Dow Chemical Company. He founded three dendrimer-based nanotechnology companies; namely: NanoSynthons LLC (2010), Dendritic Nanotechnologies Inc. (2001) (acquired by Starpharma, Melbourne, Australia) and Dendritech Inc. (1992) (acquired by the Dow Chemical Co., Midland, MI USA). Tomalia holds over 135 US patents and has over 265 peer reviewed publications largely focused on dendrimers and dendrimer-based nanomedicine. Recently, Dr. Tomalia was inducted as a AAAS Fellow (2016) for his pioneering contributions to nanotechnology and nanomedicine, particularly for the discovery of new macromolecular architectures including dendrimers, poly(oxazolines) and a new nanoperiodic concept for unifying nanoscience. Other positions currently held by Dr. Tomalia include: Scientific Advisory Board CLINAM, European Foundation for Clinical Nanomedicine; Sr. Scientific Advisor to the European Union CosmoPHOS Nano Project (2012-present). Dr. Tomalia also serves as Faculty Member, Faculty 1000 Biology; Associate Editor, Journal of Nanoparticle Research (Springer); Editorial Advisory Board, Nanomedicine (Elsevier) and Current Bionanotechnology.